Intellipharmaceutics International Inc.
IPCIQ
$0.00
$0.000.00%
OTC PK
| 08/31/2023 | 05/31/2023 | ||||
|---|---|---|---|---|---|
| Revenue | -85.69% | 47.17% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -85.69% | 47.17% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -267.64% | 47.17% | |||
| SG&A Expenses | 106.95% | -32.64% | |||
| Depreciation & Amortization | 0.25% | -0.49% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 262.80% | -18.50% | |||
| Operating Income | -5,592.36% | 89.58% | |||
| Income Before Tax | -3,392.05% | 84.79% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -3,392.05% | 84.79% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -3,392.05% | 84.79% | |||
| EBIT | -5,592.36% | 89.58% | |||
| EBITDA | -19,085.87% | 103.53% | |||
| EPS Basic | -3,468.75% | 85.05% | |||
| Normalized Basic EPS | -3,470.00% | 85.07% | |||
| EPS Diluted | -2,900.00% | 81.31% | |||
| Normalized Diluted EPS | -3,470.00% | 85.07% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||